

BIOCRYST PHARMACEUTICALS INC

Form 8-K

March 15, 2005

---

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: March 15, 2005**

**BioCryst Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware  
(State or other jurisdiction  
of incorporation)**

**000-23186  
(Commission  
File Number)**

**62-1413174  
(IRS Employer  
Identification #)**

**2190 Parkway Lake Drive, Birmingham, Alabama 35244  
(Address of Principal Executive Office)**

**(205) 444-4600  
(Registrant's telephone number, including area code)**

**Item 8.01 Other Events.**

On March 15, 2005, Registrant issued a press release announcing the successful completion of a Phase I clinical trial with oral BCX-4208 for psoriasis. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Neither the furnishing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to Registrant's Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at Registrant's Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.

**Item 9.01 Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated March 15, 2005 entitled BioCryst Pharmaceuticals Successfully Completes Phase I Trial with Oral BCX-4208 for Psoriasis .



**EXHIBIT INDEX**

<b>Item</b>	<b>Description</b>
99.1	Press release dated March 15, 2005 entitled BioCryst Pharmaceuticals Successfully Completes Phase I Trial with Oral BCX-4208 for Psoriasis .

4